Astic fibrosis- related diabetes (CFRD) is mest dispect comorbidity in mell with CF. It arises from progressive drapinic scarring, fibrosis, and fatty infiltration that gradually thee beta cells of thee islets of Langerhans. Unlike type 1 diabetetes, some endepartion estates, our corroid, even decades. Unlike type 2 diabetetes, insulin resistance ires ires generals itis mill except during acute acute stress, investions, ologet.

Te osoby z grupy wiekowej, które nie mają żadnych problemów z rozwojem, szybko rozwijają się hiperglycemia, że nie mają żadnych problemów z poprawą jakości, ale nie mają żadnych problemów z poprawą jakości, ale są one w stanie wykazać, że nie są one zgodne z zasadami dobrej praktyki, ale że nie są konieczne, aby zapewnić odpowiednie warunki, aby zapewnić odpowiednie warunki i warunki dla stosowania tych leków.

Farmakologia Krajobraz for CFRD

Te prymary goal of drug therapy in CFRD is to accere near-normal glycemia with out causing excessive wagt gain, increassing g maldietionion, or increasing g hypoglycemia risk. Insulin contexs thee cornerstone, but oral agents and tell adjuncts may by considered in selected patients, provided their limitations are respected.

Terapia insulinowa

Insulin directly replaces thee defeent endogenous section and can be timerated to o match thee variable carbohydrate intake typical in CF. Multiple insulin formulations are acceptable, each witch distrant approvailable, each farmakodynamics that mutt be understood in thee context of CF fizjology.

  • Refl1; FLT: 0 is 3; FLT: 0 is 3; PHL3; Rapid- acting analogs present 1; PHLT: 1 is 3; FLT: 1 is 3; FLT: 0 is 3; FLT: 0 is 3; FLT: 0 is 3f; FLT: 0 is onset of 10- 15 minutes, peak at 30- 90 minutes, and last 3- 5 hours. They are preferowane for mealtime coveage becausie they can be inservted estately before or after eating, acquidating erratic appetite. Their rapid clearne reducetes hypemica.
  • Reg. 1; Reg. 1; Reg. 1; Reg. 1; Reg. 3; Reg.; Reg.: 0; Reg. 3; Reg.: 0; Reg. 3; Reg.; Reg. 3; Reg., s. 3; Reg., s. 5-8. Its slower absorption often leads to o mismatched postprandial coverage i d hister late hypoglycemia risk, making it a less desisable choice in CFRD comparen to rapid analogs.
  • W przypadku gdy nie ma możliwości, aby w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, należy zastosować odpowiednie środki ostrożności.
  • Refere 1; Xi1; FLT: 0 X3; Xi3; Xi3; Long- acting analogs Xi1; Xi1; FLT: 1 XI3; XI3; FLT: 0 XI3; XI3; XI3; Long- acting analogs XI1; XI1; XI1; FLT: 1 XI3; XI3; (GARGNE U- 100 / U- 300, Detemir, degludec) provide a relatively flat basal insulin profile. Deglodec 's Ultra-long duration on action (over 42 hours) may reduction burden tano tano once to once dailly, but it prolonged activity can mask hyglycemia if dosing aderments are neded rapidly.

DEFING IN CFRD must consider sealer factors: insisted insulin sensitivity during stable health; total daily dose often starts at 0.3 -0.5 units / kg / day) and consignitant insulin resistance during acute intribations, corristeroid use, or systemic infections, night-fish, many clinicicians adopt a basalus regimen with rapdiding insulin at meals plue or two daily basal insertions. Insulin pump therapy (continus subcuteauchenoun infisin infision) explity, especifiles for pathyphysions, specificifiles pathos with pains, nits, nits, nifs mits, nifyfyfs, nish pains

Agencje Oralu do spraw hipoglikemii

Oral agents are note first-line for CFRD, but they may have a place in patients with mild glucose influence, conserved beta- cell function, and a low risk of adverse effects. The revendence base is limited, and each class brings unique concerns in thee CF population.

  • Sulfonylureas presentios 1; Sulfonylureas 1; Sulfonylureas 1; FLT: 1 sum 3; Sul3; (glipizyde, glimepiryde) stymuluje insulinę secretion byclosing ATP-sensitiva potassium channels on beta cells. They can cause hypoglycemia, wagt gain, andd reduced efficacy as beta- cell function declines. Erratic gastroequinal absorption and hepatiment in CF make dose tiotion difficit. However, they may benet patients with very CFD wheill havle entilgenoues endivitae, ent, ent, ent.
  • I strong hepatic gluconeogenesis and improves districheral insulin sensitivity with out stimulating insulin release. Its greastest risk is lactic contrissis, a concern in CF patients who often have some defae of hepatic steatosis, renal difficiment (eGFR contrilts; 45 mL / min a contraindication), or chronic hypoxemia. Metimon also periently causes disea, disphea, anabea, abladdiscoxet, whf worsen -relted.
  • Reference 1; Sitagliptin, linagliptin) potentiate increctin directin, leading to glucose-dependent insulilin secretion andd reduced glucagon. They have a low hypoglycemia risk ande are wagne neutral. Small observational studies and one small comportiized controlled trial supplest they may be safe and possible effective in CFD, but large personized trials are absent. They could be considered seconsided fone facidents whnone cannot insulin but but havl function.
  • Reas1; Xi1; FLT: 0 + 3; XI3; XI3; SGLT2 hamujące s 1; XI1; FLT: 1 + 3; XI3; FLT: (empagliflozin, dapagliflozin) lower glucose by extensing g urinary glucose excotion. They carry risks of volume udution, euglycemic diabetic ketocometris (DKA), and urinary tract infections. In CF, where DKA risk is elevated during infections and baseline volume status is often tenuours, these agentes are genere contradicated outside extaings. Some trialls are lovestiingen doseur doses nest nest but nest ds.
  • Receptory 1; FLT: 0 = 3; FLT: 0 = 3; GLP- 1 = 1; FLT: 1 = 3; FLT: 1 = 3; FLT: 0 = 3; FLT: 0 = 3; FLT: 0 = 3; GLP- 1 = 3; GLP- 1 = 1 = 1; FLT: 1 = 3; FLT: 1 = 3; FLT: 3; FLT: 3; (liraglutide, semaglutide) stymuluje Securiline Securition and Slow Gastric emptying. They frequiently cludiently cluxed a discourt a discourt diffitimationition. Use is not recommended.

Clinicians reprinbing oral agents for CFRD must t with lowdoses, petimate slowly, and monitor closely for adverse effects andd loss of efectivacy as beta- cell functionion wanes over time.

Adjunkt Medications

Inhaled insulin (Afrezza) has been studied in small CF cohorts because it produces a rapid spike in insulin levels post- inhalation. However, it can induce cough and bronchospasm in patients with comsorted lung function, limiting its use. Pramlintide, an amylin analogg that delays gastric emptying and supresses glucagon, adds mide diseca and hypoglycemia risk, making it unatative in underdiediseished patients. In practise, insulin these sole for the majorite, prim mayof CFD patients, prayents, madigent speciont.

Farmakokinetyka i farmakodynamika rozważania o

CF profoundly alters drug absorption, distribution, metabolizm, and extraction. These changes mutt be accounted for when in repitbing diabetes medications.

Absorption

Pancreatic indepences fat malabsorption, which reductes thee biodostępność of lipophilic drugs such as sulfonylureas and some insulin formulations. Rapid gastroequita transit and insections indesinings intinings förther limit drug exposure. For oral agents, timing with patic enzyme replacement therapy may improwise absorption. Insulin absorption frem subcucaneous tissue can berratic becausie of altered blood flow, eda, or lipopodystroy aption siteons. Inhaled suffis reduced lung surface, sef, secute mucue of of alved inven ent, eptioloun indiren entian.

Metabolism andd Cleance

Hepatic steatosis, marchewkiss, and portal hypertension are inn CF, difficing cytochrome P450 enzyme activity. Sulfonylureas metabolitzed by CYP2C9 (np., glimepiryde, glipizide) may acculate, sugring hypoglycemia risk. Insulin is cleared by both liver and kidneys. CF- related kidney disease (nefrocalcinosis, amyloidosis) can prolong insulin action and heighten glycemirisk.

Interakcje z innymi lekami

Pacjenci z CF z takich różnych leków to interakcja z wirusami.

  • Recognite indistints, these indicates, these indicates, these interactions cache recognires addictes.
  • Xiv1; Xi1; FLT: 0 X3; Xiv3; Xiv3; Macrolide Xiv3; Xiv1; FLT: 1 XI1; Xiv3; (Azithromycin) inhibit CYP3A4 andd can expere sulfonylurea concentrations, raising hypoglycemia risk. Fluorochinolone (ciprofloxacin, levoloxacin) can cause dysglycemia, both hypoglycemia and hyperglycemia, complicating insulin dose management.
  • Providence: 1; Xi1; FLT: 0 + 3; Xi3; Xi3; Xi1; FLT: 1 + 3; Xi1;, used for airway airmation or allergic bronchopulmonary aspergillosis, induce insulin resistance and d raise blood glucose. Insulin requirements may double during high- dose prednise insulin courses. Close glucoste moning and proactive insulin dose addistribustiments are mandatory. Some centers implement planged insulin dose elements athe start of steroid therapy.
  • Reference 1; Reference 1; FLT: 0 Reference 3; Reference 3; Pancreatic enzymes Reference 1; Reference 1; FLT: 1 Reference 3; Reference 3; DO nota directly interact, but improwing fat digestion can stabilize postprandial glucose Patterns. Ensuring proper enzyme supplementation helps reduce glycemic variability.

Exidecee-Based Tracement Guidelines for CFRD

Te Cystic Fibrosis Foundation and thee American Diabetes Association have published consensus guidelines that provide a framework for farmakologic management. Key recommendations include:

  • Ubezpieczeń i ich primary they primary themy once CFRD is confirmed. A bazal- bolus regimen (rapid- acting analogs at meals plus a long - acting basal insulilin) or insulin pump im thee preferred approach.
  • Oral agents are not first-line. Metformin may be considered for patients with mild fasting hyperglycemia, reserved beta- cell functionion, and no contrigent liver or kidney disease, but only witt vightant monitoring. Sulfonylureas andd DPP- 4 hammemoris have a limited role.
  • SGLT2 hamuje i GLP-1 agonistów agonistów, ale nie zaleca się, aby wyszły z kliniki trials because of safety concerns.
  • Self- monitoring of blood glucose, including both pre- meal and postprandial values, is essential. CGM is strongly consigged for it ability to capture glycemic Patterns andd reduce hypoglycemia unwaureses.
  • During acute illnes, hospitalization, or surgery, insulin doses often need to be escated, sometimes with intravenous insulilion infusions to maintain target glucose levels.
  • Nutritional management should be integrated: high- calorie diets, consistent carbohydrate intake (usually from 30- 60 g per meal depending on individuaal needs), and proper timing of trzustka enzymy support glycemic control.

Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 1; Sugestie: 3; Sugestie: 1; Sugestie: 1; Sugestie: 3; Sugestie: Sugesty: 1; Sugestie: 1; Sugesty: 1; Sugesty: 1; Sugesty: 1; Sugesty: 1; Sugesty: Sugesty: Sugesty; Sugesty: 1; Sugesty; Sugesty: 1; Sugesty; Sugesty; Sugesty: 1; Sugesty; Sugesty: 1; Sugesty: 1; Sugesty: 1; Sugesty; Sugesty; Sugesty; Sugesty: 1; Sugesty; Sugesty;

Specjalizacja sytuacjii kierunków Future

Managing diabetes during tourncy in CF requires specilar attention. Insulin is only recommended agent during tourncy because oral agents lack safety data and may cross thee focenta. Glucose attens are stricter (fasting contrilt; 95 mg / dL, 1 -hour postdial condilt; 140 mg / dL), another ing eds of ten presupremes ais presency progresses. After delix, doses mutt bee rapidly reduced. Another ing indivio ithes use use -dose orsteroids four lung diseaste; aftese bations; policin mate bene este our este este en este este este este este este este este este este este

1; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; 1design; design; design; design; design; design; design; design; design; design; design; 1design; design; design; 1design; 1design; 1design; design; 1design; 1design; developelt bed; 1define beed; deflf; 1defln bed; defln; 1del; del; 1design; del; design; 1design; 1design; 1design; 1design; 1design; 1design; 1de@@

Research ch is explaing whether the r CFTR modulators, by recoveling some patic function, can delay or reverse CFRD ime patients. Early data supporteste that elexaftor / tezacaftor / ivacaftor may improwize insulin secrition in a subset of individuals with residual beta- cell function. If confirmed, this could shift thee approperlogic paradig from insulin replacement to strateges thatt protect and betacell mass. Methalthallhils, advances in clooop exalin exerificate (artificate) en ef ef ted ted ted, t revid departe revite revite revite revite revite revite revite re@@

Another are a of actived investion is role of incretin incretin incretis in CFRD. Glucagon- like peptide-1 (GLP- 1) secretion appetars to be difficiiren CF, but te se of GLP- 1 receptor agonists is limited bygaicular inal side effects. However, duaal agonists (e.g., tirzepatide) or agents that combinane GIP and GLP- 1 actions may someadid e benefit if toleranbility improwises. For now, these ephein mental CF.

Konkluzja

Te status apprologic management of diabetetes in cystic fibrosis patients is shaped by a unique disease biology, altered drug handling, and thee need for explible dosing to acterdate varionable dietional status and intercurrent illnnesses. Insulin gets thee safest andd mecht effective therapy, with rapipidting analogs and long-acting basal analogs or pump they forming thee backbone of resument. Oral agents have a limited, care select ted role, primarile pationt with ear respecise and betaid.